News
Sarepta stock tanked Friday after a new patient death was uncovered, spurring an FDA request to halt shipments of an ...
Julie Hyman outlines some of the top stories on Wall Street as part of Monday, July 21's Market Minute. Navitas (NVTS) stock ...
Key Takeaways The S&P 500 and Nasdaq reached record highs Monday, while the Dow advanced as well, in the wake of several strong earnings reports.Verizon Communications shares rose after the telecom ...
US stocks rose on Monday, with fresh records for the Nasdaq Composite (^IXIC) and S&P 500 (^GSPC) in sight as Wall Street ...
1h
Barchart on MSNS&P 500 and Nasdaq 100 Jump to Record Highs as Bond Yields FallThe S&P 500 Index ($SPX) (SPY) today is up +0.54%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.41%, and the Nasdaq ...
Verizon Communications helped lead the way and rose 4.8%. The telecom reported a stronger profit for the latest quarter than ...
Most investors don’t see the drugmaker’s executive management as credible, following the failure to disclose a patient death, ...
Sarepta Therapeutics has rejected a call by the Food and Drug Administration to stop shipments of its muscular dystrophy drug.
2h
InvestorsHub on MSNSarepta Shares Drop as FDA Suspends Gene Therapy Trials for Muscular DystrophyShares of Sarepta Therapeutics Inc (NASDAQ:SRPT) plunged 10% after the company disclosed that the U.S. Food and Drug ...
2h
Investor's Business Daily on MSNSarepta's 'Unprecedented Times' Continue As Company Rebukes The FDASarepta stock took another dive Monday after the biotech company refused the FDA's request to voluntarily stop all shipments ...
CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results